Since androgen receptor (AR) signaling is critically required for the development of prostate cancer (PCa), targeting AR axis has been the standard treatment of choice for advanced and metastatic PCa. Unfortunately, although the tumor initially responds to the therapy, treatment resistance eventually develops and the disease will progress. It is therefore imperative to identify the mechanisms of therapeutic resistance and novel molecular targets that are independent of AR signaling. Recent advances in pathology, molecular biology, genetics and genomics research have revealed novel AR-independent pathways that contribute to PCa carcinogenesis and progression. They include neuroendocrine differentiation, cell metabolism, DNA damage repair pathways and immune-mediated mechanisms. The development of novel agents targeting the non-AR mechanisms holds great promise to treat PCa that does not respond to AR-targeted therapies.
Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer
Lingfan Xu,Jun-yi Chen,Wei-peng Liu,C. Liang,Hailiang Hu,Jiaoti Huang
Published 2018 in Asian Journal of Urology
ABSTRACT
PUBLICATION RECORD
- Publication year
2018
- Venue
Asian Journal of Urology
- Publication date
2018-11-28
- Fields of study
Medicine
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-96 of 96 references · Page 1 of 1
CITED BY
Showing 1-10 of 10 citing papers · Page 1 of 1